China National Accord Medicines Corporation (000028.SZ): Director and General Manager Lin Zhaoxiong has resigned.

On November 25th, Gelonghui reported that china national accord medicines corporation (000028.SZ) announced that the board of directors received Mr. Lin Zhaoxiong's resignation application on November 22, 2024. Due to adjustments in work arrangements, Mr. Lin Zhaoxiong applied to resign from his positions as director, member of the board of directors' global strategy committee, and general manager, and will not hold any other positions in the company after his resignation. As of the disclosure date of this announcement, Mr. Lin Zhaoxiong does not hold any company stocks. The board of directors agrees to authorize Mr. Li Jinxiong, deputy general manager and deputy secretary of the company's party committee, to lead the operational management during the vacancy of the general manager, with the authorization period starting from this board meeting.

Gelonghui FinanceNov 25, 2024 16:49

Insurance capital is intensively increasing stakes in dividend stocks! What is the reason?

Currently, there are quite a few shareholders of insurance funds that hold more than 5% of the circulating shares of listed companies. In addition to some being unlocked restricted shares, there have also been many actions of shareholding and new stakes taken, with at least 14 instances of such actions this year.

China brokerageNov 20, 2024 09:58

China National Accord Medicines Corporation Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Simply Wall StOct 31, 2024 06:05

China National Accord Medicines Corporation (000028): The business performance in the third quarter has improved compared to the previous quarter, bullish on the subsequent recovery.

In the first 9 months of 2024, the company's revenue/parent net income/non-parent net income were 56.466/1.066/1.024 billion yuan, -0.2%/-10.4%/-10.4% year-on-year, meeting the performance express expectations; 3.

htscOct 29, 2024 14:46

Sinopharm is consistent: report for the third quarter of 2024

SZSIOct 29, 2024 00:00 · Announcements

Sinopharm is consistent: quick performance report for the first three quarters of 2024

SZSIOct 23, 2024 00:00 · Announcements